Principal Financial Group Inc. Has $30.11 Million Position in Immunome, Inc. $IMNM

Principal Financial Group Inc. lessened its holdings in Immunome, Inc. (NASDAQ:IMNM) by 2.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,376,867 shares of the company’s stock after selling 27,583 shares during the quarter. Principal Financial Group Inc. owned approximately 1.22% of Immunome worth $30,112,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. raised its stake in shares of Immunome by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after acquiring an additional 5,003,824 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Immunome by 23.4% during the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after purchasing an additional 1,144,788 shares during the period. Primecap Management Co. CA grew its stake in shares of Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after purchasing an additional 1,667,432 shares during the last quarter. State Street Corp increased its holdings in Immunome by 37.9% in the fourth quarter. State Street Corp now owns 3,868,000 shares of the company’s stock valued at $83,085,000 after purchasing an additional 1,064,027 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in Immunome by 8,659.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after purchasing an additional 2,823,144 shares during the period. 44.58% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

IMNM has been the subject of several analyst reports. Barclays assumed coverage on Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price for the company. HC Wainwright reissued a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Citigroup reissued a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Leerink Partners lowered their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Finally, Truist Financial lifted their price objective on Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Thirteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $33.17.

Insider Transactions at Immunome

In related news, insider Robert Lechleider sold 55,000 shares of the company’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $19.85, for a total transaction of $1,091,750.00. Following the sale, the insider owned 15,805 shares in the company, valued at $313,729.25. This represents a 77.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jean Jacques Bienaime bought 10,500 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were acquired at an average cost of $19.45 per share, with a total value of $204,225.00. Following the purchase, the director directly owned 43,415 shares of the company’s stock, valued at $844,421.75. This trade represents a 31.90% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders sold 472,142 shares of company stock worth $10,262,648. Corporate insiders own 7.21% of the company’s stock.

Immunome Price Performance

IMNM opened at $22.32 on Monday. Immunome, Inc. has a twelve month low of $8.66 and a twelve month high of $27.65. The company has a fifty day moving average of $21.00 and a 200-day moving average of $21.91. The stock has a market cap of $2.53 billion, a PE ratio of -9.38 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.12. Sell-side analysts anticipate that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.